hCD98HC

Fig.1 Detection of hCD98 and mCD98 expressed in Peripheral Blood in WT C57BL /6 (female, 8 weeks old) and hCD98 mice (female, 17.5 weeks old).

Fig.2 Detection of hCD98 and mCD98 expressed in Spleen in WT C57BL/6 (female, 8 weeks old)  and hCD98 mice (female, 17.5 weeks old).

Fig.3 Detection of human CD98 expression in brain of WT C57BL/6 mice (male, 8-10 weeks old) and hCD98 knockin mice (male, 10 weeks old) by WB.

Abbr. M, marker; WT, wild type; HO, Homozygous; PC, positive control, Hela cells.

Fig.4 Detection of human CD98 expression in hCD98 knockin mice by immunofluorescent staining. CD98 was detectable in brain from both WT C57BL/6 and HO hCD98 mice, as the antibody was cross-reactived between human and mouse CD98. Co-localization between CD98 and CD31 was observed in both WT C57BL/6 and HO hCD98 mice. Brain tissues from male 8-10-week-old wild-type (WT) and homozygous hCD98 knockin mice (HO) were fixed, embedded in OCT and sectioned. Immunofluorescence staining was performed using anti-CD98 antibody and anti-mouse CD31 antibody.

Fig.5 Brain penetration rate of an anti-TD1/CD98 antibody in hCD98HC knock-in mice. Anti-hTD1/hCD98 antibody exhibited a significantly higher brain penetration rate than the anti-TD1 hIgG1 control in hCD98HC knock-in mice.

9-week-old, male homozygous hCD98HC knock-in mice were administered anti-hTD1 hIgG1 (10 mg/kg) or anti-hTD1/hCD98 hIgG1 (2+1 format, 10 mg/kg), both synthesized according to a patent, by intravenous (i.v.) injection. Serum, brain tissue, and brain parenchyma were collected at the indicated time points after dosing. Drug concentrations in serum (n=9–15 per time point), brain (n=3 per time point), and brain parenchyma (n=3 per time point) were measured by ELISA. The ratios of drug concentrations in brain and brain parenchyma relative to serum were then calculated.